Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deferasirox - Novartis

Next Previous
Drug Profile

Deferasirox - Novartis

Alternative Names: CGP-72670; Deferasirox; Exjade; ICL-670; ICL-670A; Jadenu

Latest Information Update: 21 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Novartis; University Hospital Grenoble
  • Class Antianaemics; Benzoic acids; Small molecules; Triazoles
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Iron overload
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Iron overload
  • Phase II Myelodysplastic syndromes; Thalassaemia
  • Discontinued Malaria

Most Recent Events

  • 07 Jun 2024 Novartis terminates a phase II trial in Iron overload in France, Romania, Russia, Slovakia, Switzerland, and Spain (PO) (NCT03203850) (EudraCT2016-002529-12)
  • 03 Apr 2024 Novartis withdraws a phase II trial in Iron overload in Norway (PO) (NCT01892644)
  • 15 Jan 2024 Novartis completes a phase II trial in Iron overload (In adolescents, In children) in Turkey, Tunisia, Thailand, Russia, Philippines, Panama, Oman, Malaysia, Lebanon, Italy, India, Hungary, France, Egypt, Bulgaria, Belgium, USA (PO, Granules) (NCT02435212) (EudraCT2013-004739-55)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top